ELEVAI LABS INC. - COMMON STOCK

Elevai Labs Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance

22 Nov 2024 17:23:15 By Nasdaq GlobeNewswire

Elevai Labs Inc. Announces Withdrawal of Offer to Exchange and Plans to Reassess

22 Nov 2024 16:00:04 By Nasdaq GlobeNewswire

CORRECTION - Elevai Labs Inc.

14 Nov 2024 13:35:59 By Nasdaq GlobeNewswire

Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update

14 Nov 2024 08:08:00 By Nasdaq GlobeNewswire

Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange

04 Nov 2024 16:45:39 By Nasdaq GlobeNewswire

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity

22 Oct 2024 08:54:26 By Nasdaq GlobeNewswire

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity

21 Oct 2024 06:30:00 By Nasdaq GlobeNewswire

Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock

04 Oct 2024 16:08:26 By Nasdaq GlobeNewswire

REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations

03 Oct 2024 14:45:00 By Nasdaq GlobeNewswire

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations

03 Oct 2024 06:30:00 By Nasdaq GlobeNewswire

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Launch of Clinical Study Combining Its Flagship Topical Exosome Skincare Products with a Medical Aesthetic Energy Device

02 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

Elevai Labs Inc. Announces Pricing of $8.0 Million Public Offering

23 Sep 2024 07:45:00 By Nasdaq GlobeNewswire

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Results for E-Series Exosome Technology in Potential Melasma Applications

10 Sep 2024 06:30:24 By Nasdaq GlobeNewswire

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Encouraging Data Results Indicating Potential for Hair Restoration Using Proprietary Exosome Technology

03 Sep 2024 06:30:00 By Nasdaq GlobeNewswire

Elevai Labs Inc. Files Combination Patents with Yuva Biosciences for Breakthrough Hair and Scalp Care Technology Utilizing YuvaBioⓇ Y100™ Mitochondrial Innovation and Elevai Exosomes™

28 Aug 2024 06:30:00 By Nasdaq GlobeNewswire

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Data Results with Completion of Clinical Study of Elevai Enfinity™ Topical Exosome Serum

26 Aug 2024 06:30:00 By Nasdaq GlobeNewswire

Elevai Labs Inc. Subsidiary, Elevai Research Inc., Announces Preliminary Positive Research Data Highlighting the Potential of Proprietary Exosome Technology for Skin Health Applications

19 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Elevai Labs Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

14 Aug 2024 08:05:44 By Nasdaq GlobeNewswire

Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhD

30 Jul 2024 08:00:26 By Nasdaq GlobeNewswire

Elevai Labs Inc. Subsidiary, Elevai Skincare, Announces The Elevai S-Series Hair and Scalp Care Product Line

28 Jun 2024 08:00:00 By Nasdaq GlobeNewswire